APA (7th ed.) Citation

Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., . . . Mohty, M. (2019). Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone marrow transplantation (Basingstoke), 54(11), 1815-1826. https://doi.org/10.1038/s41409-019-0536-y

Chicago Style (17th ed.) Citation

Guillaume, Thierry, et al. "Prospective Phase II Study of Prophylactic Low-dose Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute Myeloid Leukemia and Myelodysplastic Syndrome." Bone Marrow Transplantation (Basingstoke) 54, no. 11 (2019): 1815-1826. https://doi.org/10.1038/s41409-019-0536-y.

MLA (9th ed.) Citation

Guillaume, Thierry, et al. "Prospective Phase II Study of Prophylactic Low-dose Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute Myeloid Leukemia and Myelodysplastic Syndrome." Bone Marrow Transplantation (Basingstoke), vol. 54, no. 11, 2019, pp. 1815-1826, https://doi.org/10.1038/s41409-019-0536-y.